Sermorelin
A growth hormone–releasing hormone analog once marketed as an approved drug; today it is available mainly through licensed compounding pharmacies, and whether it is currently eligible is a question for the pharmacy.
What it is
Sermorelin is a synthetic version of the first 29 amino acids of growth-hormone-releasing hormone — the active core of the natural molecule. Unusually for this library, it was once an FDA-approved drug (Geref, for pediatric GH deficiency) before being discontinued for commercial reasons rather than safety ones.
That history gives it more legitimate clinical pedigree than most 'anti-aging' peptides, and it survives today mainly through compounding-pharmacy channels in adult wellness programs. The open question isn't whether it releases GH — it does — but whether raising GH pulses in aging adults produces meaningful benefits, which the trials never established.
What researchers have actually studied it for
Pediatric growth-hormone deficiency (its former approved indication) and GH-axis diagnostics; adult anti-aging use is extrapolation.
How it works
GHRH(1-29) — the fragment carrying essentially all of the parent hormone's receptor activity. It stimulates the pituitary's own GH release in natural pulses, preserving the feedback loops that direct GH injection bypasses; its action is short, mimicking the physiological signal rather than flooding it.
Where it came from
Synthesized in the wake of GHRH's 1982 discovery, sermorelin became Geref, approved for diagnosing and treating pediatric GH deficiency. It was withdrawn from the US market in 2008 for business reasons, then found a second life as the compounding world's flagship 'GH optimization' peptide.
What the research record actually contains
- Pediatric GH-deficiency trials supporting its former approval.
- Diagnostic-use literature for GH-axis testing.
- Small adult studies showing raised GH/IGF-1 and exploratory endpoints in aging — hypothesis-level, never definitive.
- No controlled trials demonstrating body-composition, recovery or longevity outcomes in healthy adults.
What's known about risks
Its approved-era record was benign — injection-site reactions and flushing led the list. The unanswered question for wellness use is chronic-elevation safety in older adults: GH excess has known metabolic and proliferative risks, and no long-term trial has cleared casual use.
Where it stands legally
No current approved product; availability runs through compounding pharmacies, whose eligibility to prepare it is a live question only a licensed pharmacy can answer on a given day.
Worth asking a licensed provider
- 1.What specifically are we trying to change, and how will we measure it — IGF-1 alone isn't an outcome?
- 2.Which licensed pharmacy compounds it, and what's its current eligibility status?
- 3.What glucose and IGF-1 monitoring will we run, and what would make us stop?